Newsroom

NEW YORK--(BUSINESS WIRE)--Elysian, the first AI-native Third-Party Administrator (TPA) purpose-built for complex commercial claims, today announced the appointment of Zack Moy as Chief Technology Officer. Moy has spent 15 years working on a specific class of engineering problem: how to give structure to unstructured data so that knowledge workers can make better, faster decisions. At Elysian, that work meets its most consequential application yet. Commercial claims generate dense, ambiguous in...

BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN : FR0014007ZB4 – Mnémonique : AELIS, éligible PEA-PME), société biopharmaceutique au stade clinique spécialisée dans le développement de traitements des maladies cérébrales et périphériques impliquant le récepteur CB1, annonce aujourd’hui ses résultats annuels pour l’exercice clos au 31 décembre 2025. Pier Vincenzo Piazza, Directeur Général d’Aelis Farma, déclare : « L’année 2025 a été marquée par de nouvelles avancées dans l...

BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces its full year results for the year ended December 31, 2025. Pier Vincenzo Piazza, CEO of Aelis Farma, stated: “The year 2025 was marked by further progress in the clinical development of our two drug candidates, AEF0117 and AEF021...

SAN DIEGO--(BUSINESS WIRE)--Certis Oncology, an AI-enabled translational science company, today announced the launch of Certis Oncology Intelligence®, an integrated platform designed to generate data-driven insights into therapeutic response by combining predictive modeling, agentic AI-enabled biological data exploration, and functional validation in clinically relevant cancer models. Certis Oncology Intelligence represents a new approach to translational research—one that connects computationa...

倫敦--(BUSINESS WIRE)--(美國商業資訊)-- 菁英障礙超越聯盟(PJL)正式啟動，賽事設立創紀錄的3億美元保底獎金池，開啟障礙超越運動的新紀元。 PJL由McCourt Global及其執行董事長Frank McCourt提供支援，是一項具有開創性的全球賽事，旨在讓高水準騎手和馬匹在世界舞臺上占據應有的地位。PJL以實力、誠信和卓越為基石，匯聚全球頂尖運動員，角逐該運動史上的最高額獎金池，協助這項運動建構更具韌性、更長期的財務模式。 PJL將設立16支參賽隊伍，並在250名全球頂尖騎手中採用業界首創的騎手選拔機制。 一系列世界一流的沉浸式賽事將在歐洲、北美和中東的14座代表性國際場館舉辦，讓觀眾前所未見地近距離感受高規格障礙超越運動的拼搏、美感和力量。 第一個賽季將於2027年3月至10月舉行。 PJL旨在向新受眾普及這項運動，同時尊重其傳統底蘊，將頂尖競技表現與頂級娛樂體驗相結合。聯賽與艾美獎得獎製作公司Box to Box Films達成合作，並採用免費轉播模式，進一步強化賽事吸引力。尖端技術、高度透明和創新團隊賽制提升了這項頂尖運動賽事的懸念、強度和競技對抗性，...

伦敦--(BUSINESS WIRE)--(美国商业资讯)-- 超级障碍马术联赛(PJL)正式启动，赛事设立创纪录的3亿美元保底奖金池，开启障碍马术运动的新纪元。 PJL由McCourt Global及其执行董事长Frank McCourt鼎力支持，是一项具有开创性的全球赛事，旨在让高水平骑手和马匹在世界舞台上占据应有的地位。PJL以实力、诚信和卓越为基石，汇聚全球顶尖运动员，角逐该项目史上的最高额奖金池，助力这项运动构建更具韧性、更长期的财务模式。 PJL将设立16支参赛队伍，并在250名全球顶尖骑手中采用行业首创的骑手选拔机制。 一系列世界级沉浸式赛事将在欧洲、北美和中东的14座标志性国际场馆举办，让观众前所未有地近距离感受高规格障碍马术运动的拼搏、美感和力量。 首个赛季将于2027年3月至10月举行。 PJL旨在向新受众普及这项运动，同时尊重其传统底蕴，将顶尖竞技表现与高端娱乐体验相结合。联赛与艾美奖获奖制作公司Box to Box Films达成合作，并采用免费转播模式，进一步强化赛事吸引力。前沿技术、高度透明和创新团队赛制提升了这项顶级体育赛事的悬念、强度和竞技对抗性，在不违...

MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced the presentation of new post-hoc analyses of 12‑month real‑world data from the TRACE study of tralokinumab, at the 2026 American Academy of Dermatology (AAD) Annual Meeting. TRACE is a prospective, non-interventional, international study evaluating adult patients receiving tralokinumab, with analyses assessing minimal disease activity and outcomes in patient subgroups, including those with H&...

DALLAS--(BUSINESS WIRE)--Lyons & Simmons, LLP, is proud to announce that all nine of its attorneys have been named to the 2026 Texas Super Lawyers and Rising Stars lists, a significant increase from six firm honorees the year before. The firm’s 2026 Texas Super Lawyers honorees are Michael Lyons, Chris Simmons, Chris Carr, Wes Black, and Stephen Higdon. This marks the first Super Lawyers selection for Mr. Higdon after eight consecutive years being recognized on the companion Rising Stars li...

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 23/03/2026 FR0014000MR3 48 000 61.1218 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 23/03/2026 FR0014000MR3 12 000 61.2959 CEUX EUROFINS SCIENTIFIC 529900JEHFM...

RAHWAY, N.J.--(BUSINESS WIRE)--Enlicitide, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions Compared to Oral Non-Statin Therapies...